Rapid Micro Biosystems Reports 10.9% Revenue Growth in Q2 2026 Despite Increased Net Loss

Rapid Micro Biosystems, Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of $8.1 million, a 10.9% increase from $7.3 million in the same period last year. The growth was primarily driven by a 10.1% rise in product revenue, which reached $5.3 million, and a 12.5% increase in service revenue, totaling $2.8 million. Despite this revenue growth, the company incurred a net loss of $12.9 million, slightly higher than the $11.9 million loss reported in the prior year, reflecting ongoing challenges in achieving profitability.

In the first half of 2026, Rapid Micro's total revenue increased by 11% to $16.1 million compared to $14.5 million in the same period of 2025. Product revenue surged by 22% to $10.9 million, while service revenue decreased by 6.7% to $5.2 million. The company’s gross margin improved significantly, reaching $1.6 million, or 9.9% of total revenue, compared to $0.7 million, or 4.7%, in the previous year. This improvement in gross margin was attributed to higher sales volumes and a favorable product mix, despite increased costs associated with product and service revenue.

Operationally, Rapid Micro has made strides in expanding its customer base and product adoption. As of June 30, 2026, the company had placed a total of 200 Growth Direct systems with approximately 50 customers, including 75% of the top 20 largest pharmaceutical companies. The number of validated systems also increased, with 169 cumulative validations reported, indicating a growing acceptance of the Growth Direct platform in the market. The company continues to focus on enhancing customer engagement and expanding its sales and marketing efforts to drive further adoption.

In terms of financial health, Rapid Micro's cash and cash equivalents stood at $14.7 million as of June 30, 2026, down from $20.0 million at the end of 2025. The company has also entered into a Loan and Security Agreement with Trinity Capital Inc., providing access to up to $45 million in debt financing, which is expected to support its operational needs and growth initiatives. However, the company cautioned that if its revenue growth and cost management strategies do not materialize as planned, it may need to seek additional funding or scale back its expansion plans.

Looking ahead, Rapid Micro aims to leverage its partnerships, including a distribution agreement with MilliporeSigma, to enhance its market presence and drive revenue growth. The company is also implementing cost reduction measures to improve operational efficiency and is optimistic about achieving positive cash flow in the future, contingent on meeting certain commercial and operational milestones.